Biosimilars | Current Treatment | Oncology | US/EU | 2018
Recent launches of trastuzumab biosimilars (Celltrion/Mundipharma’s Herzuma, Samsung Bioepis/Merck & Co.’s Ontruzant, Amgen/Allergan’s Kanjinti) have expanded the biosimilar sector of the European oncology market. In the United States, only two oncology biosimilars are available (Sandoz’s Zarxio [filgrastim] and Mylan’s Fulphila [pegfilgrastim]), but biosimilars of trastuzumab and bevacizumab were recently approved and are due to launch in 2019, following the patent expiriesof Herceptin and Avastin, respectively. Uptake of these biosimilars, as well as biosimilars of granulocyte colony-stimulating factor (G-CSF) and erythropoiesis-stimulating agent (ESA) biosimilars, will depend on the prescribing behavior of oncologists. To help manufacturers/marketers of oncology biosimilars and brands understand the opinions, actions, and expectations of these physicians, Decision Resources Group has conducted primary market research with oncologists in France, Germany, and the United States on the use of branded drugs versus their biosimilar competitors.
Questions answered:
What is the current patient share of oncology biosimilars, and what expectations do oncologists have for future patient shares, assuming additional biosimilars launch?
How similar do oncologists believe biosimilars are to their reference brands?
What factors do oncologists identify as being the key drivers and barriers to biosimilar uptake?
What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
What cost reduction is required for a biosimilar to achieve more than a 50% patient share?